Genentech buys Regor's CDK inhibitors for breast cancer

Genentech has announced an agreement with Regor Pharmaceuticals to acquire Regor's next-generation CDK inhibitors, aimed at treating breast cancer. This acquisition includes an initial payment of $850 million, with further financial commitments based on the achievement of specific development, regulatory, and commercial milestones. As part of the deal, Genentech will oversee clinical development, manufacturing, and global commercialization of these inhibitors.

Regor Pharmaceuticals will continue to manage two ongoing phase 1 trials until they are completed. Post-acquisition, Regor will shift its focus to advancing other key areas within its portfolio, including oncology, metabolic diseases, and autoimmune disorders that are not covered under this agreement.

Apart from the CDK inhibitors, Regor possesses other promising assets. These include RGT-075, a GLP-1 receptor agonist that shows potential for treating obesity and related conditions, and RGT-419B, a CDK4 inhibitor that could be effective against advanced breast cancer resistant to standard therapies. Additionally, Regor is exploring immune-modulatory drugs such as HPK1 inhibitors for cancer immunotherapy.

The agreement reflects Genentech's commitment to expanding its oncology portfolio and pioneering innovative treatments for challenging conditions like breast cancer. This strategic move is aimed at leveraging Regor's advanced research to potentially offer new therapeutic options for patients worldwide.